413 related articles for article (PubMed ID: 33721519)
1. Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy : A Multinational Prospective Cohort Study.
Chammartin F; Lodi S; Logan R; Ryom L; Mocroft A; Kirk O; d'Arminio Monforte A; Reiss P; Phillips A; El-Sadr W; Hatleberg CI; Pradier C; Bonnet F; Law M; De Wit S; Sabin C; Lundgren JD; Bucher HC;
Ann Intern Med; 2021 Jun; 174(6):768-776. PubMed ID: 33721519
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.
Lodi S; Phillips A; Logan R; Olson A; Costagliola D; Abgrall S; van Sighem A; Reiss P; Miró JM; Ferrer E; Justice A; Gandhi N; Bucher HC; Furrer H; Moreno S; Monge S; Touloumi G; Pantazis N; Sterne J; Young JG; Meyer L; Seng R; Dabis F; Vandehende MA; Pérez-Hoyos S; Jarrín I; Jose S; Sabin C; Hernán MA;
Lancet HIV; 2015 Aug; 2(8):e335-43. PubMed ID: 26423376
[TBL] [Abstract][Full Text] [Related]
3. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
[TBL] [Abstract][Full Text] [Related]
4. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.
Molina JM; Grund B; Gordin F; Williams I; Schechter M; Losso M; Law M; Ekong E; Mwelase N; Skoutelis A; Wiselka MJ; Vandekerckhove L; Benfield T; Munroe D; Lundgren JD; Neaton JD;
Lancet HIV; 2018 Apr; 5(4):e172-e180. PubMed ID: 29352723
[TBL] [Abstract][Full Text] [Related]
5. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
[TBL] [Abstract][Full Text] [Related]
6. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
Siegfried N; Uthman OA; Rutherford GW
Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.
Kunisaki KM; Niewoehner DE; Collins G; Aagaard B; Atako NB; Bakowska E; Clarke A; Corbelli GM; Ekong E; Emery S; Finley EB; Florence E; Infante RM; Kityo CM; Madero JS; Nixon DE; Tedaldi E; Vestbo J; Wood R; Connett JE;
Lancet Respir Med; 2016 Dec; 4(12):980-989. PubMed ID: 27773665
[TBL] [Abstract][Full Text] [Related]
8. Association of Viral Suppression With Lower AIDS-Defining and Non-AIDS-Defining Cancer Incidence in HIV-Infected Veterans: A Prospective Cohort Study.
Park LS; Tate JP; Sigel K; Brown ST; Crothers K; Gibert C; Goetz MB; Rimland D; Rodriguez-Barradas MC; Bedimo RJ; Justice AC; Dubrow R
Ann Intern Med; 2018 Jul; 169(2):87-96. PubMed ID: 29893768
[TBL] [Abstract][Full Text] [Related]
9. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.
Mussini C; Lorenzini P; Cozzi-Lepri A; Lapadula G; Marchetti G; Nicastri E; Cingolani A; Lichtner M; Antinori A; Gori A; d'Arminio Monforte A;
Lancet HIV; 2015 Mar; 2(3):e98-106. PubMed ID: 26424550
[TBL] [Abstract][Full Text] [Related]
10. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
; Cain LE; Logan R; Robins JM; Sterne JA; Sabin C; Bansi L; Justice A; Goulet J; van Sighem A; de Wolf F; Bucher HC; von Wyl V; Esteve A; Casabona J; del Amo J; Moreno S; Seng R; Meyer L; Perez-Hoyos S; Muga R; Lodi S; Lanoy E; Costagliola D; Hernan MA
Ann Intern Med; 2011 Apr; 154(8):509-15. PubMed ID: 21502648
[TBL] [Abstract][Full Text] [Related]
11. Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients.
Kiertiburanakul S; Boettiger D; Lee MP; Omar SF; Tanuma J; Ng OT; Durier N; Phanuphak P; Ditangco R; Chaiwarith R; Kantipong P; Lee CK; Mustafa M; Saphonn V; Ratanasuwan W; Merati TP; Kumarasamy N; Wong WW; Zhang F; Pham TT; Pujari S; Choi JY; Yunihastuti E; Sungkanuparph S; ;
J Int AIDS Soc; 2014; 17(1):18804. PubMed ID: 24598459
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.
Palella FJ; Deloria-Knoll M; Chmiel JS; Moorman AC; Wood KC; Greenberg AE; Holmberg SD;
Ann Intern Med; 2003 Apr; 138(8):620-6. PubMed ID: 12693883
[TBL] [Abstract][Full Text] [Related]
13. Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study.
Caniglia EC; Cain LE; Sabin CA; Robins JM; Logan R; Abgrall S; Mugavero MJ; Hernández-Díaz S; Meyer L; Seng R; Drozd DR; Seage GR; Bonnet F; Dabis F; Moore RD; Reiss P; van Sighem A; Mathews WC; Del Amo J; Moreno S; Deeks SG; Muga R; Boswell SL; Ferrer E; Eron JJ; Napravnik S; Jose S; Phillips A; Justice AC; Tate JP; Gill J; Pacheco A; Veloso VG; Bucher HC; Egger M; Furrer H; Porter K; Touloumi G; Crane H; Miro JM; Sterne JA; Costagliola D; Saag M; Hernán MA; ;
Lancet HIV; 2017 Jun; 4(6):e251-e259. PubMed ID: 28411091
[TBL] [Abstract][Full Text] [Related]
14. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
Ledergerber B; Egger M; Erard V; Weber R; Hirschel B; Furrer H; Battegay M; Vernazza P; Bernasconi E; Opravil M; Kaufmann D; Sudre P; Francioli P; Telenti A
JAMA; 1999 Dec; 282(23):2220-6. PubMed ID: 10605973
[TBL] [Abstract][Full Text] [Related]
15. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
Phillips AN; Staszewski S; Weber R; Kirk O; Francioli P; Miller V; Vernazza P; Lundgren JD; Ledergerber B; ; ;
JAMA; 2001 Nov; 286(20):2560-7. PubMed ID: 11722270
[TBL] [Abstract][Full Text] [Related]
16. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
17. When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study.
Caniglia EC; Sabin C; Robins JM; Logan R; Cain LE; Abgrall S; Mugavero MJ; Hernandez-Diaz S; Meyer L; Seng R; Drozd DR; Seage GR; Bonnet F; Dabis F; Moore RR; Reiss P; van Sighem A; Mathews WC; Del Amo J; Moreno S; Deeks SG; Muga R; Boswell SL; Ferrer E; Eron JJ; Napravnik S; Jose S; Phillips A; Olson A; Justice AC; Tate JP; Bucher HC; Egger M; Touloumi G; Sterne JA; Costagliola D; Saag M; Hernán MA;
J Acquir Immune Defic Syndr; 2016 Jun; 72(2):214-21. PubMed ID: 26895294
[TBL] [Abstract][Full Text] [Related]
18. From CD4-Based Initiation to Treating All HIV-Infected Adults Immediately: An Evidence-Based Meta-analysis.
Song A; Liu X; Huang X; Meyers K; Oh DY; Hou J; Xia W; Su B; Wang N; Lu X; Xia H; Yang X; Chen H; Wu H
Front Immunol; 2018; 9():212. PubMed ID: 29487595
[TBL] [Abstract][Full Text] [Related]
19. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.
Tenorio AR; Zheng Y; Bosch RJ; Krishnan S; Rodriguez B; Hunt PW; Plants J; Seth A; Wilson CC; Deeks SG; Lederman MM; Landay AL
J Infect Dis; 2014 Oct; 210(8):1248-59. PubMed ID: 24795473
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of patients infected with HIV through use of injected drugs compared to patients infected through sexual transmission: late presentation, delayed anti-retroviral treatment and higher mortality.
Suárez-García I; Sobrino-Vegas P; Dalmau D; Rubio R; Iribarren JA; Blanco JR; Gutierrez F; Montero Alonso M; Bernal E; Vinuesa García D; Del Amo J;
Addiction; 2016 Jul; 111(7):1235-45. PubMed ID: 26890155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
